valproic acid has been researched along with Cognition Disorders in 124 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is approved by the Food and Drug Administration (FDA) for the treatment of manic or mixed episodes associated with bipolar disorder." | 7.83 | Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I. ( Hassamal, S; Reese, K; Testa, C; Waller, S, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 7.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| "Phenobarbital was associated with a higher rate of drug withdrawal although there was no evidence to suggest that phenobarbital caused more adverse events compared to carbamazepine, valproic acid or phenytoin." | 6.47 | Side effects of phenobarbital in epilepsy: a systematic review. ( Li, YP; Zeng, LN; Zhang, LL, 2011) |
| "Valproic acid treated animals were treated from 5 days preceding behavioral testing in the Morris water maze at a clinically relevant concentration." | 5.42 | Standard dose valproic acid does not cause additional cognitive impact in a rodent model of intractable epilepsy. ( Jellett, AP; Jenks, K; Lucas, M; Scott, RC, 2015) |
| "To review and summarize the currently available data on the use of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate) in the treatment of behavioral and psychological symptoms of dementia (BPSD); to determine whether these medications can be recommended for routine clinical use." | 4.84 | Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. ( Konovalov, S; Muralee, S; Tampi, RR, 2008) |
| " In this study, the effect of antidepressant sertraline (SRT) in combination with AEDs sodium valproate (SV) and levetiracetam (LEV) on seizures, cognitive impairment and oxidative stress in rats was evaluated." | 4.02 | Response to sertraline and antiepileptic drugs in pentylenetetrazole kindling in rats. ( Hussain, M; Katyal, J; Rashid, H, 2021) |
| " Children exposed to monotherapy levetiracetam (n = 42), topiramate (n = 27), or valproate (n = 47) and a group of children born to women who had untreated epilepsy (n = 55) were enrolled retrospectively from the UK Epilepsy and Pregnancy Register." | 3.83 | Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. ( Baker, GA; Bromley, RL; Calderbank, R; Cheyne, CP; Clayton-Smith, J; García-Fiñana, M; Irwin, B; Morrow, JI; Rooney, C; Shallcross, R; Trayner, P, 2016) |
| "Valproic acid (VPA) is approved by the Food and Drug Administration (FDA) for the treatment of manic or mixed episodes associated with bipolar disorder." | 3.83 | Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I. ( Hassamal, S; Reese, K; Testa, C; Waller, S, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 3.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| "A single treatment of valproate and olanzapine did not ameliorate the hyperactivity or abnormal anxiety level of DGKβ KO mice." | 3.81 | The effects of valproate and olanzapine on the abnormal behavior of diacylglycerol kinase β knockout mice. ( Hara, H; Ishisaka, M; Mizoguchi, T; Shimazawa, M; Tsujii, S; Tsuruma, K, 2015) |
| " We investigated for the first time whether class I histone deacetylase inhibitor valproic acid (VPA) can reverse cognitive deficits in a mouse model of sepsis-associated encephalopathy (SAE)." | 3.79 | Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy. ( Dong, L; Ji, M; Jia, M; Qiu, L; Wu, J; Yang, J; Zhang, G; Zhang, M, 2013) |
| "Combination therapy with valproic acid plus quetiapine is recommended as one of the first-line approaches to treatment of manic or mixed episodes in patients with bipolar disorder." | 3.77 | Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. ( De Dios, C; Fudio, S; Lorenzo, A, 2011) |
| "Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder." | 3.69 | Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series. ( Locke, CA; Mayer, PV; Stoll, AL; Vuckovic, A, 1996) |
| " TPM is introduced at 25 mg and increased with weekly 25mg/d increments to a minimum dosage of 200 mg/d." | 2.69 | A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. ( Aldenkamp, AP; Baker, G; Chadwick, D; Cooper, P; de Haan, GJ; Doelman, J; Duncan, R; Gassmann-Mayer, C; Hughson, C; Hulsman, J; Mulder, OG; Overweg, J; Pledger, G; Rentmeester, TW; Riaz, H; Wroe, S, 2000) |
| "Phenobarbital was associated with a higher rate of drug withdrawal although there was no evidence to suggest that phenobarbital caused more adverse events compared to carbamazepine, valproic acid or phenytoin." | 2.47 | Side effects of phenobarbital in epilepsy: a systematic review. ( Li, YP; Zeng, LN; Zhang, LL, 2011) |
| "Sporadic Alzheimer's disease (SAD) is a slowly progressive neurological disorder that is the most common form of dementia." | 1.46 | Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system. ( El Sayed, NSED; Sorial, ME, 2017) |
| "Valproic acid treated animals were treated from 5 days preceding behavioral testing in the Morris water maze at a clinically relevant concentration." | 1.42 | Standard dose valproic acid does not cause additional cognitive impact in a rodent model of intractable epilepsy. ( Jellett, AP; Jenks, K; Lucas, M; Scott, RC, 2015) |
| "Benign myoclonic epilepsy in infancy (BMEI) is a well-defined electro-clinical syndrome, classically associated with a good prognosis." | 1.40 | [Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome]. ( Carreras-Sáez, I; Domínguez-Carral, J; Fournier-Del Castillo, MC; García-Peñas, JJ; Jiménez-Echevarría, S; Pérez-Jiménez, MÁ, 2014) |
| "Epileptic myoclonus is generally treated by valproate monotherapy, and this therapy has confirmed efficacy." | 1.38 | Stepwise synchronization through the corpus callosum is one cause of myoclonic jerks. ( Arai, H; Iimura, Y; Nakajima, M; Sugano, H, 2012) |
| "At 14 years after smoke inhalation injury, he had persistent cognitive impairment." | 1.38 | Progressive neuropsychiatric and brain abnormalities after smoke inhalation. ( Tobe, E, 2012) |
| "Forty-four patients with rolandic epilepsy (32 boys, 12 girls), aged from 5 to 14 years, were examined in the prospective study during 5 years." | 1.37 | [Transitory cognitive dysfunction in rolandic epilepsy]. ( Buchneva, IA; Ermakov, AIu; Ermolenko, NA; Voronkova, KV, 2011) |
| " Our findings also suggest that ethnic traits may affect carnitine bioavailability as well as cognitive outcomes in this clinical context." | 1.36 | Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. ( Abramson, RK; Cuturic, M; Hardin, JW; Moran, RR, 2010) |
| " The subjects had 11 plasma samples drawn over a dosing interval on days 1, 15, and 30." | 1.35 | Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. ( Cruttenden, K; DiCenzo, R; Gelbard, H; Hochreiter, J; Mariuz, P; Peterson, DR; Rezk, NL; Schifitto, G, 2008) |
| " This case report indicates that even non-chronic MDMA use may cause subacute toxic encephalopathy in which the clinical evolution is paralleled by neuroimaging changes in specific cerebral areas." | 1.35 | Hippocampal remodelling after MDMA neurotoxicity: a single case study. ( Amistà, P; Battaglia, M; Bertagnoni, GE; Carollo, C; Costanzo, R; Lupi, A; Martinuzzi, A; Nifosì, F; Perini, G; Toffanin, T; Vestri, A, 2009) |
| "Children with West syndrome have better seizure control and development, if the treatment is started within 1 month of onset of symptoms." | 1.35 | Outcome in West syndrome. ( Sharma, NL; Vishwanthan, V, 2008) |
| "Early epilepsy is known to worsen the developmental prognosis of young children with a congenital focal brain lesion, but its direct role is often very difficult to delineate from the other variables." | 1.35 | The role of epilepsy in early language development in a child with a congenital lesion in the right hemisphere. ( Deonna, T; Maeder-Ingvar, M; Mayor-Dubois, C; Roulet-Perez, E, 2008) |
| "Epilepsy is often the most important clinical manifestation of the syndrome, even if its appearance is not constantly precocious." | 1.35 | Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children. ( Canevini, MP; Dalla Bernardina, B; Darra, F; Fiorini, E; La Selva, L; Lazzarotto, F; Piazzini, A; Vignoli, A; Zucca, C, 2009) |
| "Kainic acid-induced seizures, a rodent model of human temporal lobe epilepsy, strongly induce the proliferation of DG neurogenic progenitor cells and are also associated with long-term cognitive impairment." | 1.34 | Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. ( Clemenson, GD; Gage, FH; Hsieh, J; Jessberger, S; Mathews, E; Mejia, E; Nakashima, K; Ogawa, S; Sinton, CM; Ure, K, 2007) |
| "Ten cases of reversible parkinsonism associated with VPA in 6 women and 4 men, associated with marked cognitive impairment in six cases, are described." | 1.33 | Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. ( Andréjak, M; Gras-Champel, V; Masmoudi, K; Masson, H, 2006) |
| "Valproic acid (VPA) has the potential to benefit patients suffering from human immunodeficiency virus (HIV)-associated cognitive impairment." | 1.32 | Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. ( Cruttenden, K; DiCenzo, R; Gelbard, H; Morse, G; Peterson, D; Riggs, G; Schifitto, G, 2004) |
| "Total remission of seizures occurred in 52%." | 1.30 | Long-term outcomes of conventional therapy for infantile spasms. ( Clarke, SL; Griesemer, DA; Holden, KR, 1997) |
| " Reduction of VPA dosage and subsequent discontinuation 4 months later resulted in disappearance of clinical symptoms with a 20-point improvement at IQ testing and recovery of previous PM score." | 1.30 | Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. ( Belmonte, A; Canapicchi, R; Casalini, C; Guerrini, R; Perucca, E, 1998) |
| "In particular, memory deficits, attentional problems, psychomotor slowing and reading and writing difficulties are highlighted, and the impact of the seizures, brain damage, and anticonvulsant drugs on cognitive function noted." | 1.27 | [Cognitive effects of antiepileptic drugs]. ( Trimble, R, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (9.68) | 18.7374 |
| 1990's | 16 (12.90) | 18.2507 |
| 2000's | 51 (41.13) | 29.6817 |
| 2010's | 44 (35.48) | 24.3611 |
| 2020's | 1 (0.81) | 2.80 |
| Authors | Studies |
|---|---|
| Hussain, M | 1 |
| Rashid, H | 1 |
| Katyal, J | 1 |
| Zucker, I | 1 |
| Bloch, J | 1 |
| Miranda, MJ | 1 |
| Agah, E | 1 |
| Asgari-Rad, N | 1 |
| Ahmadi, M | 1 |
| Tafakhori, A | 1 |
| Aghamollaii, V | 1 |
| Jamal, I | 1 |
| Kumar, V | 1 |
| Vatsa, N | 1 |
| Shekhar, S | 1 |
| Singh, BK | 1 |
| Sharma, A | 1 |
| Jana, NR | 1 |
| Yu, H | 1 |
| Yang, X | 1 |
| Tang, X | 1 |
| Tang, R | 1 |
| Lin, Y | 2 |
| Li, X | 1 |
| Lao, G | 1 |
| Jiang, Z | 1 |
| Ye, B | 1 |
| Lin, W | 1 |
| Liu, Y | 1 |
| Cao, L | 1 |
| Wu, J | 1 |
| Dong, L | 1 |
| Zhang, M | 2 |
| Jia, M | 1 |
| Zhang, G | 1 |
| Qiu, L | 1 |
| Ji, M | 1 |
| Yang, J | 1 |
| Domínguez-Carral, J | 1 |
| García-Peñas, JJ | 1 |
| Pérez-Jiménez, MÁ | 1 |
| Fournier-Del Castillo, MC | 1 |
| Carreras-Sáez, I | 1 |
| Jiménez-Echevarría, S | 1 |
| Verrotti, A | 1 |
| Scaparrotta, A | 1 |
| Cofini, M | 1 |
| Chiarelli, F | 1 |
| Tiboni, GM | 1 |
| Kozicky, JM | 2 |
| Torres, IJ | 2 |
| Silveira, LE | 2 |
| Bond, DJ | 1 |
| Lam, RW | 1 |
| Yatham, LN | 2 |
| Lovett, M | 1 |
| Skidmore, DL | 1 |
| Mohamed, IS | 1 |
| Sundin, JR | 1 |
| Øksengård, AR | 1 |
| Røste, LS | 1 |
| Svendsen, J | 1 |
| Ihle-Hansen, H | 1 |
| Muralidharan, K | 1 |
| Bücker, J | 1 |
| Trivisano, M | 1 |
| Specchio, N | 1 |
| Vigevano, F | 1 |
| Sharma, S | 1 |
| Taliyan, R | 1 |
| Jellett, AP | 1 |
| Jenks, K | 1 |
| Lucas, M | 1 |
| Scott, RC | 1 |
| Ishisaka, M | 1 |
| Tsujii, S | 1 |
| Mizoguchi, T | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Anderson, M | 1 |
| Egunsola, O | 1 |
| Cherrill, J | 1 |
| Millward, C | 1 |
| Fakis, A | 1 |
| Choonara, I | 1 |
| Juliandi, B | 1 |
| Tanemura, K | 1 |
| Igarashi, K | 1 |
| Tominaga, T | 1 |
| Furukawa, Y | 1 |
| Otsuka, M | 1 |
| Moriyama, N | 1 |
| Ikegami, D | 1 |
| Abematsu, M | 1 |
| Sanosaka, T | 1 |
| Tsujimura, K | 1 |
| Narita, M | 1 |
| Kanno, J | 1 |
| Nakashima, K | 2 |
| Gelisse, P | 1 |
| Genton, P | 1 |
| Crespel, A | 1 |
| Welbat, JU | 1 |
| Chaisawang, P | 1 |
| Chaijaroonkhanarak, W | 1 |
| Prachaney, P | 1 |
| Pannangrong, W | 1 |
| Sripanidkulchai, B | 1 |
| Wigmore, P | 1 |
| Yang, Y | 1 |
| Cheng, Z | 1 |
| Tang, H | 1 |
| Jiao, H | 1 |
| Sun, X | 1 |
| Cui, Q | 1 |
| Luo, F | 1 |
| Pan, H | 1 |
| Ma, C | 1 |
| Li, B | 1 |
| Bromley, RL | 2 |
| Calderbank, R | 1 |
| Cheyne, CP | 1 |
| Rooney, C | 1 |
| Trayner, P | 1 |
| Clayton-Smith, J | 4 |
| García-Fiñana, M | 1 |
| Irwin, B | 1 |
| Morrow, JI | 1 |
| Shallcross, R | 1 |
| Baker, GA | 3 |
| Hassamal, S | 1 |
| Waller, S | 1 |
| Reese, K | 1 |
| Testa, C | 1 |
| Tournikioti, K | 1 |
| Ferentinos, P | 1 |
| Michopoulos, I | 1 |
| Alevizaki, M | 1 |
| Soldatos, CR | 1 |
| Dikeos, D | 1 |
| Douzenis, A | 1 |
| Sorial, ME | 1 |
| El Sayed, NSED | 1 |
| DiCenzo, R | 2 |
| Peterson, DR | 1 |
| Cruttenden, K | 2 |
| Mariuz, P | 1 |
| Rezk, NL | 1 |
| Hochreiter, J | 1 |
| Gelbard, H | 2 |
| Schifitto, G | 2 |
| Nifosì, F | 1 |
| Martinuzzi, A | 1 |
| Toffanin, T | 1 |
| Costanzo, R | 1 |
| Vestri, A | 1 |
| Battaglia, M | 1 |
| Bertagnoni, GE | 1 |
| Lupi, A | 1 |
| Amistà, P | 1 |
| Carollo, C | 1 |
| Perini, G | 1 |
| Sharma, NL | 1 |
| Vishwanthan, V | 1 |
| Mayor-Dubois, C | 1 |
| Maeder-Ingvar, M | 1 |
| Deonna, T | 1 |
| Roulet-Perez, E | 1 |
| Schreur, L | 1 |
| Middeljans-Tijssen, CW | 1 |
| Hengstman, GJ | 1 |
| Olde Rikkert, MG | 1 |
| Harden, CL | 2 |
| Meador, KJ | 3 |
| Pennell, PB | 2 |
| Hauser, WA | 2 |
| Gronseth, GS | 2 |
| French, JA | 2 |
| Wiebe, S | 2 |
| Thurman, D | 2 |
| Koppel, BS | 2 |
| Kaplan, PW | 2 |
| Robinson, JN | 2 |
| Hopp, J | 2 |
| Ting, TY | 2 |
| Gidal, B | 2 |
| Hovinga, CA | 2 |
| Wilner, AN | 2 |
| Vazquez, B | 2 |
| Holmes, L | 2 |
| Krumholz, A | 2 |
| Finnell, R | 2 |
| Hirtz, D | 2 |
| Le Guen, C | 2 |
| Bonnín, CM | 1 |
| Martínez-Arán, A | 2 |
| Torrent, C | 2 |
| Pacchiarotti, I | 1 |
| Rosa, AR | 1 |
| Franco, C | 1 |
| Murru, A | 1 |
| Sanchez-Moreno, J | 2 |
| Vieta, E | 2 |
| Battino, D | 1 |
| Vignoli, A | 1 |
| Canevini, MP | 1 |
| Darra, F | 1 |
| La Selva, L | 1 |
| Fiorini, E | 1 |
| Piazzini, A | 1 |
| Lazzarotto, F | 1 |
| Zucca, C | 2 |
| Dalla Bernardina, B | 1 |
| Maccotta, L | 1 |
| Sullivan, JE | 1 |
| Umka, J | 1 |
| Mustafa, S | 1 |
| ElBeltagy, M | 1 |
| Thorpe, A | 1 |
| Latif, L | 1 |
| Bennett, G | 1 |
| Wigmore, PM | 1 |
| Koh, MT | 1 |
| Haberman, RP | 1 |
| Foti, S | 1 |
| McCown, TJ | 1 |
| Gallagher, M | 1 |
| Cuturic, M | 1 |
| Abramson, RK | 1 |
| Moran, RR | 1 |
| Hardin, JW | 1 |
| Beato, R | 1 |
| Maia, DP | 1 |
| Teixeira, AL | 1 |
| Cardoso, F | 1 |
| Liukkonen, E | 1 |
| Kantola-Sorsa, E | 1 |
| Paetau, R | 1 |
| Gaily, E | 1 |
| Peltola, M | 1 |
| Granström, ML | 1 |
| Kálmán, J | 2 |
| Mawer, G | 2 |
| Love, J | 1 |
| Kelly, J | 1 |
| Purdy, L | 1 |
| McEwan, L | 1 |
| Briggs, M | 1 |
| Shi, X | 1 |
| Sin, X | 1 |
| Piccinelli, P | 1 |
| Beghi, E | 1 |
| Borgatti, R | 1 |
| Ferri, M | 1 |
| Giordano, L | 1 |
| Romeo, A | 1 |
| Termine, C | 1 |
| Viri, M | 1 |
| Balottin, U | 1 |
| De Dios, C | 1 |
| Fudio, S | 1 |
| Lorenzo, A | 1 |
| Zhang, LL | 1 |
| Zeng, LN | 1 |
| Li, YP | 1 |
| Iimura, Y | 1 |
| Sugano, H | 1 |
| Nakajima, M | 1 |
| Arai, H | 1 |
| Pinheiro, RM | 1 |
| de Lima, MN | 1 |
| Fries, GR | 1 |
| Garcia, VA | 1 |
| Presti-Torres, J | 1 |
| Hallmenschlager, LH | 1 |
| Alcalde, LA | 1 |
| Roesler, R | 1 |
| Andersen, ML | 1 |
| Quevedo, J | 1 |
| Kapczinski, F | 1 |
| Schröder, N | 1 |
| Xuan, A | 1 |
| Long, D | 1 |
| Li, J | 1 |
| Ji, W | 1 |
| Hong, L | 1 |
| Zhang, W | 1 |
| Ermolenko, NA | 1 |
| Ermakov, AIu | 1 |
| Voronkova, KV | 1 |
| Buchneva, IA | 1 |
| Tobe, E | 1 |
| Corradini, I | 1 |
| Donzelli, A | 1 |
| Antonucci, F | 1 |
| Welzl, H | 1 |
| Loos, M | 1 |
| Martucci, R | 1 |
| De Astis, S | 1 |
| Pattini, L | 1 |
| Inverardi, F | 1 |
| Wolfer, D | 1 |
| Caleo, M | 1 |
| Bozzi, Y | 1 |
| Verderio, C | 1 |
| Frassoni, C | 1 |
| Braida, D | 1 |
| Clerici, M | 1 |
| Lipp, HP | 1 |
| Sala, M | 1 |
| Matteoli, M | 1 |
| Haghighi, M | 1 |
| Bajoghli, H | 1 |
| Bigdelou, G | 1 |
| Jahangard, L | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Arkhipov, VI | 1 |
| Shevchenko, NA | 1 |
| Reif, A | 1 |
| Hamelbeck, B | 1 |
| Pfuhlmann, B | 1 |
| Loring, DW | 1 |
| Hulihan, JF | 1 |
| Kamin, M | 1 |
| Karim, R | 1 |
| Neumann, NU | 1 |
| Bretschneider, S | 1 |
| Bullacher, Ch | 1 |
| Frasch, K | 1 |
| Hess, R | 1 |
| Wittek, R | 1 |
| Berroya, AG | 1 |
| McIntyre, J | 1 |
| Webster, R | 1 |
| Lah, S | 1 |
| Sabaz, M | 1 |
| Lawson, J | 1 |
| Bleasel, AF | 1 |
| Bye, AM | 1 |
| Colom, F | 1 |
| Reinares, M | 1 |
| Benabarre, A | 1 |
| Goikolea, JM | 1 |
| Brugué, E | 1 |
| Daban, C | 1 |
| Salamero, M | 1 |
| Duggal, HS | 1 |
| Adab, N | 3 |
| Kini, U | 3 |
| Vinten, J | 3 |
| Ayres, J | 1 |
| Baker, G | 2 |
| Coyle, H | 1 |
| Fryer, A | 2 |
| Gorry, J | 2 |
| Gregg, J | 2 |
| Nicolaides, P | 1 |
| Pickering, L | 1 |
| Tunnicliffe, L | 1 |
| Chadwick, DW | 1 |
| Peterson, D | 1 |
| Morse, G | 1 |
| Riggs, G | 1 |
| Barkai, G | 1 |
| Goshen, E | 1 |
| Tzila Zwas, S | 1 |
| Dolberg, OT | 1 |
| Pick, CG | 1 |
| Bonne, O | 1 |
| Schreiber, S | 1 |
| Scholtes, FB | 1 |
| Hendriks, MP | 1 |
| Renier, WO | 2 |
| Eriksson, K | 1 |
| Viinikainen, K | 1 |
| Mönkkönen, A | 1 |
| Aikiä, M | 1 |
| Nieminen, P | 1 |
| Heinonen, S | 1 |
| Kälviäinen, R | 1 |
| Wong, GK | 1 |
| Poon, WS | 1 |
| Pavuluri, MN | 1 |
| Schenkel, LS | 1 |
| Aryal, S | 1 |
| Harral, EM | 1 |
| Hill, SK | 1 |
| Herbener, ES | 1 |
| Sweeney, JA | 1 |
| Masmoudi, K | 1 |
| Gras-Champel, V | 1 |
| Masson, H | 1 |
| Andréjak, M | 1 |
| Perucca, E | 2 |
| Tomson, T | 1 |
| Sugden, SG | 1 |
| Kile, SJ | 1 |
| Farrimond, DD | 1 |
| Hilty, DM | 1 |
| Bourgeois, JA | 1 |
| Chinnasamy, D | 1 |
| Rudd, R | 1 |
| Velakoulis, D | 1 |
| Donati, F | 1 |
| Gobbi, G | 1 |
| Campistol, J | 1 |
| Rapatz, G | 1 |
| Daehler, M | 1 |
| Sturm, Y | 1 |
| Aldenkamp, AP | 4 |
| Galimberti, CA | 1 |
| Diegoli, M | 1 |
| Sartori, I | 1 |
| Uggetti, C | 1 |
| Brega, A | 1 |
| Tartara, A | 1 |
| Arbustini, E | 1 |
| Herrmann, N | 2 |
| Lanctôt, KL | 1 |
| Rothenburg, LS | 1 |
| Eryavec, G | 1 |
| Cysique, LA | 1 |
| Maruff, P | 1 |
| Brew, BJ | 1 |
| Gaubert, ML | 1 |
| Cougnaud, A | 1 |
| Ghali, A | 1 |
| Bruhat, C | 1 |
| Diquet, B | 1 |
| Berrut, G | 1 |
| Hessen, E | 1 |
| Lossius, MI | 1 |
| Reinvang, I | 1 |
| Gjerstad, L | 1 |
| Ristić, AJ | 1 |
| Vojvodić, N | 1 |
| Janković, S | 1 |
| Sindelić, A | 1 |
| Sokić, D | 1 |
| Gildengers, AG | 1 |
| Butters, MA | 1 |
| Chisholm, D | 1 |
| Rogers, JC | 1 |
| Holm, MB | 1 |
| Bhalla, RK | 1 |
| Seligman, K | 1 |
| Dew, MA | 1 |
| Reynolds, CF | 1 |
| Kupfer, DJ | 1 |
| Mulsant, BH | 1 |
| Hommet, C | 1 |
| Mondon, K | 1 |
| de Toffol, B | 1 |
| Constans, T | 1 |
| Nicolai, J | 1 |
| Huizenga, JR | 1 |
| Teune, LK | 1 |
| Brouwer, OF | 1 |
| Jessberger, S | 1 |
| Clemenson, GD | 1 |
| Mejia, E | 1 |
| Mathews, E | 1 |
| Ure, K | 1 |
| Ogawa, S | 1 |
| Sinton, CM | 1 |
| Gage, FH | 1 |
| Hsieh, J | 1 |
| Senturk, V | 1 |
| Goker, C | 1 |
| Bilgic, A | 1 |
| Olmez, S | 1 |
| Tugcu, H | 1 |
| Oncu, B | 1 |
| Atbasoglu, EC | 1 |
| Konovalov, S | 1 |
| Muralee, S | 1 |
| Tampi, RR | 1 |
| Ances, BM | 1 |
| Letendre, SL | 1 |
| Alexander, T | 1 |
| Ellis, RJ | 1 |
| Somerville, ER | 1 |
| Bruni, J | 1 |
| Skjødt, T | 1 |
| Sørensen, T | 1 |
| Dam, M | 1 |
| Marescaux, C | 1 |
| Warter, JM | 1 |
| Micheletti, G | 1 |
| Rumbach, L | 1 |
| Coquillat, G | 1 |
| Kurtz, D | 1 |
| Helmstaedter, C | 1 |
| Wagner, G | 1 |
| Elger, CE | 1 |
| Alpherts, WC | 1 |
| Blennow, G | 1 |
| Elmqvist, D | 1 |
| Heijbel, J | 1 |
| Nilsson, HL | 1 |
| Sandstedt, P | 1 |
| Tonnby, B | 1 |
| Wåhlander, L | 1 |
| Wosse, E | 1 |
| Stoll, AL | 1 |
| Locke, CA | 1 |
| Vuckovic, A | 1 |
| Mayer, PV | 1 |
| Armon, C | 1 |
| Shin, C | 1 |
| Miller, P | 1 |
| Carwile, S | 1 |
| Brown, E | 1 |
| Edinger, JD | 1 |
| Paul, RG | 1 |
| Holden, KR | 1 |
| Clarke, SL | 1 |
| Griesemer, DA | 1 |
| Guerrini, R | 1 |
| Belmonte, A | 1 |
| Canapicchi, R | 1 |
| Casalini, C | 1 |
| Read, CL | 1 |
| Stephen, LJ | 1 |
| Stolarek, IH | 1 |
| Paul, A | 1 |
| Sills, GJ | 1 |
| Brodie, MJ | 1 |
| Shulman, KI | 1 |
| Straussberg, R | 1 |
| Kivity, S | 1 |
| Weitz, R | 1 |
| Harel, L | 1 |
| Gadoth, N | 1 |
| Pandhi, P | 1 |
| Balakrishnan, S | 1 |
| Goldberg, JF | 2 |
| Sacks, MH | 1 |
| Kocsis, JH | 1 |
| Mulder, OG | 1 |
| Chadwick, D | 1 |
| Cooper, P | 1 |
| Doelman, J | 1 |
| Duncan, R | 1 |
| Gassmann-Mayer, C | 1 |
| de Haan, GJ | 1 |
| Hughson, C | 1 |
| Hulsman, J | 1 |
| Overweg, J | 1 |
| Pledger, G | 1 |
| Rentmeester, TW | 1 |
| Riaz, H | 1 |
| Wroe, S | 1 |
| Villosladaa, P | 1 |
| Borrás, C | 1 |
| Montalbán, X | 1 |
| Burdick, KE | 1 |
| Ronen, GM | 1 |
| Meaney, BF | 1 |
| Cunningham, C | 1 |
| Deckers, CL | 1 |
| Hekster, YA | 1 |
| Keyser, A | 1 |
| van Lier, HJ | 1 |
| Meinardi, H | 1 |
| Paty, J | 1 |
| Bourgeois, M | 1 |
| Lhermitte, F | 1 |
| Marteau, R | 1 |
| Serdaru, M | 1 |
| Dodrill, CB | 1 |
| Gallassi, R | 1 |
| Morreale, A | 1 |
| Di Sarro, R | 1 |
| Marra, M | 1 |
| Lugaresi, E | 1 |
| Baruzzi, A | 1 |
| Vanhooren, GT | 1 |
| Boyd, O | 1 |
| Whittingham, F | 1 |
| Clements, D | 1 |
| Rhodes, J | 1 |
| Selten, JP | 1 |
| Trimble, MR | 1 |
| Trimble, R | 1 |
| McLachlan, RS | 1 |
| Lanska, DJ | 1 |
| Osorio, I | 1 |
| Kido, H | 1 |
| Mizuno, Y | 1 |
| Yamaguchi, N | 1 |
| Kurata, K | 1 |
| Wason, S | 1 |
| Savitt, D | 1 |
| Larrieu, JL | 1 |
| Lagueny, A | 1 |
| Julien, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI[NCT01044758] | Phase 2 | 96 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| Changes in Serum miRNA and BDNF Levels in Bipolar II Depression Treated by Theta-burst Stimulation: A Randomized Sham-controlled Exploratory Study[NCT04998097] | 60 participants (Anticipated) | Interventional | 2022-05-23 | Recruiting | |||
| Medications After Adolescent Bariatric Surgery Protocol for Inadequate Weight Loss Following Sleeve Gastrectomy in Adolescents and Young Adults: A Pilot Feasibility Study[NCT04572217] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to No available funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance. (NCT01044758)
Timeframe: 2 weeks
| Intervention | percent correct recalled (Mean) |
|---|---|
| aMCI_62.5 | 38 |
| aMCI_62.5 Placebo | 33 |
| aMCI_125 | 33 |
| aMCI_125 Placebo | 28 |
| aMCI_250 | 34 |
| aMCI_250 Placebo | 31 |
| Age Matched Control | 44 |
Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects. (NCT01044758)
Timeframe: 2 weeks
| Intervention | mean beta coefficient (Mean) |
|---|---|
| aMCI_62.5 | -0.1203 |
| aMCI_62.5 Placebo | 0.4353 |
| aMCI_125 | -0.2238 |
| aMCI_125 Placebo | 0.8814 |
| aMCI_250 | 0.3928 |
| aMCI_250 Placebo | 0.4825 |
| Age Matched Control | -.02507 |
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
14 reviews available for valproic acid and Cognition Disorders
| Article | Year |
|---|---|
Risk mitigation for children exposed to drugs during gestation: A critical role for animal preclinical behavioral testing.
Topics: Analgesics; Animals; Behavior, Animal; Child; Cognition Disorders; Female; Humans; Pregnancy; Prenat | 2017 |
[Scientific evidence on treatment and prognosis of childhood absence epilepsy].
Topics: Anticonvulsants; Child; Cognition Disorders; Comorbidity; Electroencephalography; Epilepsy, Absence; | 2017 |
Developmental neurotoxicity and anticonvulsant drugs: a possible link.
Topics: Animals; Anticonvulsants; Breast Feeding; Carbamazepine; Cognition Disorders; Developmental Disabili | 2014 |
Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Cognition Disorders; Contraindications; | 2009 |
Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurolo
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Birth Weight; Cognition Disorders; Contraindications; | 2009 |
[Sense and sensibility: bipolar affective disorder as a battlefield of cognitions and emotions--lamotrigine therapy as a peacekeeper].
Topics: Adolescent; Adult; Affect; Aged; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Child; Clinica | 2010 |
Side effects of phenobarbital in epilepsy: a systematic review.
Topics: Anticonvulsants; Carbamazepine; Child; Cognition Disorders; Cohort Studies; Cross-Over Studies; Data | 2011 |
[Persisting deficits after severe depression].
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Cognition Disor | 2003 |
Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review.
Topics: Aggression; Amines; Anticonvulsants; Carbamazepine; Cognition Disorders; Cyclohexanecarboxylic Acids | 2008 |
Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders.
Topics: Antiretroviral Therapy, Highly Active; Brain; Citalopram; Cognition Disorders; HIV Infections; Human | 2008 |
Bipolar disorder in old age.
Topics: Acute Disease; Adult; Age Factors; Aged; AIDS Dementia Complex; Antidepressive Agents; Antimanic Age | 1999 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Problems in the assessment of cognitive effects of antiepileptic drugs.
Topics: Anticonvulsants; Cognition; Cognition Disorders; Epilepsy; Humans; Neuropsychological Tests; Researc | 1992 |
Antiepileptic drugs, cognitive function, and behavior in children: evidence from recent studies.
Topics: Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; Cognition; Cognition Disorders; Epilepsy; | 1990 |
12 trials available for valproic acid and Cognition Disorders
| Article | Year |
|---|---|
Assessment of cognitive impairments and seizure characteristics in electroconvulsive therapy with and without sodium valproate in manic patients.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Cognition Disorders; Combined Modality Therapy; Double-Bli | 2013 |
Differential cognitive and behavioral effects of topiramate and valproate.
Topics: Adolescent; Adult; Affect; Anticonvulsants; Attention; Behavior; Carbamazepine; Cognition; Cognition | 2003 |
Cognitive deterioration and electrical status epilepticus during slow sleep.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Cognition Disorders; Electroe | 2005 |
Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Cognition; Cognition Disorders; Drug Combinations | 2006 |
A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Cognition Disorders; Double | 2007 |
Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study.
Topics: Cognition; Cognition Disorders; Cohort Studies; Dose-Response Relationship, Drug; Female; HIV Infect | 2006 |
Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Attention; Carbamazepine; Cognition; Cognition Disorders; | 2006 |
Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Cognition Disorders; Epilepsy; Female; Humans; Hyperammonemia; M | 2007 |
Withdrawal of antiepileptic medication in children--effects on cognitive function: The Multicenter Holmfrid Study.
Topics: Adolescent; Carbamazepine; Child; Cognition; Cognition Disorders; Epilepsy; Female; Follow-Up Studie | 1993 |
Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cognition Disorders; Dose-Response Relation | 1998 |
A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Cognition; Cognition Disorders; Drug Therapy, Com | 2000 |
Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Cognition Disorders; Double-Blind Method; Drug Ad | 2001 |
98 other studies available for valproic acid and Cognition Disorders
| Article | Year |
|---|---|
Response to sertraline and antiepileptic drugs in pentylenetetrazole kindling in rats.
Topics: Animals; Anticonvulsants; Avoidance Learning; Cognition Disorders; Convulsants; Glutathione; Kindlin | 2021 |
Evaluating executive function in patients with temporal lobe epilepsy using the frontal assessment battery.
Topics: Adolescent; Adult; Anticonvulsants; Cognition Disorders; Epilepsy, Temporal Lobe; Executive Function | 2017 |
Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.
Topics: Angelman Syndrome; Animals; Anxiety; Brain; Cell Line, Transformed; Cognition Disorders; Disease Mod | 2017 |
Effects of spontaneous recurrent seizures on cognitive function via modulation of SNAREs expression.
Topics: Animals; Anticonvulsants; Cognition Disorders; Disease Models, Animal; Escape Reaction; Excitatory A | 2018 |
Monotherapy with lithium or valproate or respectively combination therapy with quetiapine have similar effect on cognitive functions in Chinese euthymic patients with bipolar disorder: a cross-sectional survey.
Topics: Adult; Antimanic Agents; Bipolar Disorder; China; Cognition Disorders; Cross-Sectional Studies; Dibe | 2013 |
Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy.
Topics: Animals; Brain Diseases; Brain-Derived Neurotrophic Factor; Carbazoles; Cecum; Cognition Disorders; | 2013 |
[Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome].
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; Cognition | 2014 |
Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; British Columbia; Cognition Disorders; Di | 2014 |
Valproate-induced pseudoatrophy: expanding the clinical and imaging spectrum.
Topics: Anticonvulsants; Atrophy; Brain; Child; Cognition Disorders; Humans; Magnetic Resonance Imaging; Mag | 2014 |
[Woman in her 70s with rapidly increasing cognitive impairment].
Topics: Aged; Anti-Bacterial Agents; Anticonvulsants; Borrelia burgdorferi; Ceftriaxone; Cognition Disorders | 2014 |
Are cognitive deficits similar in remitted early bipolar I disorder patients treated with lithium or valproate? Data from the STOP-EM study.
Topics: Antimanic Agents; Bipolar Disorder; Cognition Disorders; Female; Humans; Lithium Compounds; Male; Ne | 2015 |
Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
Topics: Age of Onset; Anticonvulsants; Autistic Disorder; Benzodiazepines; Cadherins; Child; Clobazam; Cogni | 2015 |
Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Brain; Brain-Derived Neurotrophic Factor; Cogniti | 2015 |
Standard dose valproic acid does not cause additional cognitive impact in a rodent model of intractable epilepsy.
Topics: Animals; Animals, Newborn; Anticonvulsants; Cognition; Cognition Disorders; Disease Models, Animal; | 2015 |
The effects of valproate and olanzapine on the abnormal behavior of diacylglycerol kinase β knockout mice.
Topics: Animals; Anxiety; Benzodiazepines; Cognition Disorders; Diacylglycerol Kinase; Disease Models, Anima | 2015 |
A prospective study of adverse drug reactions to antiepileptic drugs in children.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cognition Disorders; Drug Thera | 2015 |
Reduced Adult Hippocampal Neurogenesis and Cognitive Impairments following Prenatal Treatment of the Antiepileptic Drug Valproic Acid.
Topics: Animals; Anticonvulsants; Cognition Disorders; Female; Gene Expression Regulation, Developmental; Hi | 2015 |
Is there a difference between various presentations of valproate for cognitive outcome after in utero exposure?
Topics: Anticonvulsants; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; P | 2016 |
Kaempferia parviflora extract ameliorates the cognitive impairments and the reduction in cell proliferation induced by valproic acid treatment in rats.
Topics: Animals; Cell Proliferation; Cognition; Cognition Disorders; Doublecortin Protein; Herb-Drug Interac | 2016 |
Neonatal Maternal Separation Impairs Prefrontal Cortical Myelination and Cognitive Functions in Rats Through Activation of Wnt Signaling.
Topics: Animals; Animals, Newborn; Anxiety; Cognition Disorders; Demyelinating Diseases; Enzyme Inhibitors; | 2017 |
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate.
Topics: Adult; Anticonvulsants; Child; Cognition Disorders; Cross-Sectional Studies; Epilepsy; Female; Follo | 2016 |
Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Diagnostic and Statistical Manual of | 2016 |
Clinical and treatment-related predictors of cognition in bipolar disorder: focus on visual paired associative learning.
Topics: Adult; Analysis of Variance; Association Learning; Attention; Bipolar Disorder; Cognition Disorders; | 2017 |
Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Diseas | 2017 |
Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
Topics: Adult; Anticonvulsants; Atazanavir Sulfate; Cognition Disorders; Drug Interactions; Drug Therapy, Co | 2008 |
Hippocampal remodelling after MDMA neurotoxicity: a single case study.
Topics: Adolescent; Anticonvulsants; Body Temperature Regulation; Cognition Disorders; Electroencephalograph | 2009 |
Outcome in West syndrome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Brain; Child, Preschool; Cognition Disorders; Electroe | 2008 |
The role of epilepsy in early language development in a child with a congenital lesion in the right hemisphere.
Topics: Anticonvulsants; Brain; Child; Cognition Disorders; Electroencephalography; Epilepsy; Functional Lat | 2008 |
[Cognitive impairment and parkinsonism due to use of sodium valproate].
Topics: Aged; Anticonvulsants; Cognition Disorders; Epilepsy; Humans; Male; Parkinson Disease, Secondary; Re | 2009 |
Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study.
Topics: Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Female; Fol | 2010 |
Cognitive outcome after exposure to antiepileptic drugs in utero.
Topics: Anticonvulsants; Child, Preschool; Cognition Disorders; Dose-Response Relationship, Drug; Female; Hu | 2009 |
Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children.
Topics: Adult; Age of Onset; Anticonvulsants; Child; Chromosomes, Human, Pair 20; Cognition Disorders; Comor | 2009 |
Epilepsy: Should valproate be avoided during childbearing years?
Topics: Anticonvulsants; Brain; Child Development; Child, Preschool; Cognition Disorders; Female; Humans; Pr | 2009 |
Valproic acid reduces spatial working memory and cell proliferation in the hippocampus.
Topics: Animals; Anticonvulsants; Brain-Derived Neurotrophic Factor; Cell Proliferation; Cognition; Cognitio | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review.
Topics: Adult; Aged; Antimanic Agents; Black or African American; Brain Diseases, Metabolic; Carnitine; Cogn | 2010 |
Executive functioning in adult patients with Sydenham's chorea.
Topics: Adolescent; Adult; Age of Onset; Anti-Bacterial Agents; Anti-Dyskinesia Agents; Anticonvulsants; Cho | 2010 |
Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome.
Topics: Adolescent; Anticonvulsants; Child; Cognition Disorders; Drug Therapy, Combination; Electroencephalo | 2010 |
Early cognitive development in children born to women with epilepsy: a prospective report.
Topics: Age Factors; Anticonvulsants; Child; Child of Impaired Parents; Cognition; Cognition Disorders; Deve | 2010 |
Neuropsychological and behavioural aspects in children and adolescents with idiopathic epilepsy at diagnosis and after 12 months of treatment.
Topics: Adolescent; Anticonvulsants; Attention; Carbamazepine; Chi-Square Distribution; Child; Child, Presch | 2010 |
Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Cytochrome P-450 CYP3A; Dibenzothiaze | 2011 |
Stepwise synchronization through the corpus callosum is one cause of myoclonic jerks.
Topics: Anticonvulsants; Cognition Disorders; Corpus Callosum; Cortical Synchronization; Drug Resistance; El | 2012 |
Early life stress exacerbates cognitive dysfunction induced by d-amphetamine: amelioration by valproic acid.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Body Weight; Central Nervous System S | 2012 |
Neuroprotective effects of valproic acid following transient global ischemia in rats.
Topics: Acetylation; Animals; Blotting, Western; Cell Death; Cognition Disorders; Enzyme-Linked Immunosorben | 2012 |
[Transitory cognitive dysfunction in rolandic epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Drug Therapy, Combination | 2011 |
Progressive neuropsychiatric and brain abnormalities after smoke inhalation.
Topics: Activities of Daily Living; Brain; Cognition Disorders; Depressive Disorder, Major; DNA Damage; Fluo | 2012 |
Epileptiform activity and cognitive deficits in SNAP-25(+/-) mice are normalized by antiepileptic drugs.
Topics: Animals; Anticonvulsants; Association Learning; Brain; Carbamazepine; Cognition Disorders; Epilepsy; | 2014 |
Extinction of operant behavior as the test for cognitive disorders induced with kainic acid.
Topics: Animals; Anticonvulsants; Cognition Disorders; Conditioning, Operant; Extinction, Psychological; Kai | 2002 |
Acute akinetic crisis with marked cognitive impairment due to Valproate treatment.
Topics: Acute Disease; Antimanic Agents; Cognition Disorders; Female; Humans; Hypokinesia; Middle Aged; Valp | 2003 |
Speech and language deterioration in benign rolandic epilepsy.
Topics: Anomia; Anticonvulsants; Carbamazepine; Cerebral Cortex; Child; Child, Preschool; Cognition Disorder | 2004 |
Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Chlorpromazine; Cognition Disorders; Dysthymic Disorde | 2004 |
Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis?
Topics: Acute Disease; Anticonvulsants; Cognition Disorders; Fructose; Humans; Psychiatric Status Rating Sca | 2004 |
The longer term outcome of children born to mothers with epilepsy.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorde | 2004 |
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Area Under Curve; Benzoxazines; Cognition Disorder | 2004 |
Acetazolamide-enhanced neuroSPECT scan reveals functional impairment after minimal traumatic brain injury not otherwise discernible.
Topics: Acetazolamide; Adult; Brain; Brain Injuries; Carbonic Anhydrase Inhibitors; Cognition Disorders; Hum | 2004 |
Neuropsychological effects of exposure to anticonvulsant medication in utero.
Topics: Adolescent; Anticonvulsants; Brain; Child; Cognition Disorders; Cohort Studies; Epilepsy; Female; Hu | 2005 |
Children exposed to valproate in utero--population based evaluation of risks and confounding factors for long-term neurocognitive development.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cognition Disorders; Confounding Factors, Epidemiologic; | 2005 |
Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anthropometry; Anticonvulsants; Carbamazepine; Child; Child | 2006 |
Use of phenytoin and other anticonvulsant prophylaxis in patients with aneurysmal subarachnoid hemorrhage.
Topics: Cognition Disorders; Drug Interactions; Humans; Intracranial Aneurysm; Nimodipine; Phenytoin; Seizur | 2005 |
Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bi | 2006 |
Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases.
Topics: Aged; Anticonvulsants; Cognition Disorders; Epilepsy; Female; Humans; Male; Middle Aged; Parkinsonia | 2006 |
Prenatal exposure to antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cognition Disorders; Diethylcarbamazine; Face; Female; | 2006 |
Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury.
Topics: Adult; Aggression; Amantadine; Cognition Disorders; Conduct Disorder; Donepezil; Frontal Lobe; Human | 2006 |
A case of schizophrenia with complete agenesis of the corpus callosum.
Topics: Adult; Agenesis of Corpus Callosum; Antidepressive Agents; Antipsychotic Agents; Cognition Disorders | 2006 |
Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation.
Topics: Adult; Aged; Anticonvulsants; Atrophy; Brain; Child; Cognition Disorders; Developmental Disabilities | 2006 |
Loss of autonomy related to valproic acid intake.
Topics: Aged, 80 and over; Cognition Disorders; Humans; Male; Parkinson Disease, Secondary; Valproic Acid | 2006 |
The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cognition Disorders; Drug Administration Schedule; Drug Th | 2006 |
Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Diso | 2007 |
Reversible cognitive and neurological symptoms during valproic acid therapy.
Topics: Aged, 80 and over; Anticonvulsants; Ataxia; Cognition Disorders; Humans; Male; Seizures; Valproic Ac | 2007 |
Epigenetic modulation of seizure-induced neurogenesis and cognitive decline.
Topics: Action Potentials; Animals; Cognition Disorders; Epigenesis, Genetic; Female; Hippocampus; Neurons; | 2007 |
Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Diagnostic and Statistic | 2007 |
Tonic status epilepticus presenting as confusional state.
Topics: Adolescent; Cognition Disorders; Confusion; Diazepam; Electroencephalography; Humans; Male; Methylph | 1983 |
[Stupor associated with the treatment of epilepsy with valproate].
Topics: Anticonvulsants; Cognition Disorders; Consciousness Disorders; Epilepsy, Tonic-Clonic; Female; Human | 1984 |
Summing up of the success so far gained through choice of drugs or combinations of drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Cognition Disorders; Drug Therapy, Combination; Epilepsy; Hum | 1984 |
Stuporous episodes during treatment with sodium valproate: report of seven cases.
Topics: Anticonvulsants; Cognition Disorders; Consciousness Disorders; Electroencephalography; Epilepsy; Fem | 1982 |
Differential effects of first antiepileptic drug application on cognition in lesional and non-lesional patients with epilepsy.
Topics: Attention; Brain Damage, Chronic; Carbamazepine; Cognition Disorders; Electroencephalography; Epilep | 1993 |
Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.
Topics: Adult; Bipolar Disorder; Cognition Disorders; Creativity; Drug Administration Schedule; Drug Therapy | 1996 |
Reversible parkinsonism and cognitive impairment with chronic valproate use.
Topics: Adult; Aged; Analysis of Variance; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson | 1996 |
Long-term outcomes of conventional therapy for infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Cerebral Palsy; Cognition Disorders; Female; Humans; I | 1997 |
Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment.
Topics: Atrophy; Brain; Brain Diseases; Child; Cognition Disorders; Diagnosis, Differential; Electroencephal | 1998 |
Reversible cortical atrophy and cognitive decline induced by valproic acid.
Topics: Adolescent; Anticonvulsants; Atrophy; Cerebral Cortex; Cognition Disorders; Electroencephalography; | 1998 |
Cognitive dysfunction induced by phenytoin and valproate in rats: effect of nitric oxide.
Topics: Animals; Anticonvulsants; Arginine; Cognition Disorders; Enzyme Inhibitors; Female; Male; Memory; Ni | 1999 |
Low-dose lithium augmentation of divalproex in geriatric mania.
Topics: Acute Disease; Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Dose-Response Relation | 2000 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
[Cognitive impairment caused by valproate].
Topics: Aged; Anticonvulsants; Cognition Disorders; Female; Humans; Valproic Acid | 2000 |
Neuropsychological assessment in children with absence epilepsy.
Topics: Bias; Child; Cognition Disorders; Epilepsy, Absence; Humans; Neuropsychological Tests; Psychometrics | 2001 |
[Risk of psychotropic drug potentiation by dipropylacetamide (16 cases)].
Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents; Cognition Disorders; Drug Synergism; Drug Thera | 1978 |
[Dipropylacetate (sodium valproate) and carbamazepine : a suspicious anticonvulsant combination].
Topics: Carbamazepine; Cognition Disorders; Confusion; Drug Therapy, Combination; Epilepsy; Humans; Male; Mi | 1978 |
Cognitive effects of antiepileptic drug discontinuation.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Cognition; Cognition Disorders; Epilepsy; Humans; | 1992 |
[Valproic acid and stupor].
Topics: Carnitine; Cognition Disorders; Humans; Male; Middle Aged; Valproic Acid | 1991 |
Petit mal status: an unusual cause of confusion.
Topics: Cognition Disorders; Confusion; Electroencephalography; Epilepsy, Absence; Humans; Male; Middle Aged | 1990 |
[Valproic acid and stupor].
Topics: Cognition Disorders; Humans; Substance-Related Disorders; Valproic Acid | 1990 |
[Cognitive effects of antiepileptic drugs].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cognition Disorders; Epilepsy; | 1987 |
Pseudoatrophy of the brain with valproic acid monotherapy.
Topics: Adolescent; Atrophy; Brain; Cerebral Ventricles; Cognition Disorders; Electroencephalography; Epilep | 1987 |
Valproic acid loading during intensive monitoring.
Topics: Adult; Cognition Disorders; Confusion; Female; Humans; Valproic Acid | 1988 |
Episodic twilight state with severe autonomic symptoms in an epileptic patient.
Topics: Amygdala; Autonomic Nervous System; Carbamazepine; Child; Cognition Disorders; Consciousness Disorde | 1988 |
Acute valproic acid toxicity at therapeutic concentrations.
Topics: Child; Cognition Disorders; Confusion; Female; Humans; Substance-Related Disorders; Valproic Acid | 1985 |
[State of confusion induced by valproic acid and reversed after administration of clonazepam].
Topics: Adult; Benzodiazepinones; Clonazepam; Cognition Disorders; Confusion; Drug Therapy, Combination; Ele | 1985 |